Lead Product(s) : Enarodustat
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONNARO (enarodustat) is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was approved for the treatment of non-dialysis-dependent patients with anemia caused by chronic kidney disease.
Product Name : Onnaro
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Enarodustat
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
